IIFL downgraded Sanofi India to Reduce from ADD earlier with a target price of Rs 8,125. The stock continues to underperform domestic market growth. New launches remain limited and muted volume growth is seen in the top 3 therapies.
| Subscribe To Our Free Newsletter |
